Zymeworks (ZYME)

Executive Summary

Zymeworks is a clinical-stage biopharmaceutical company that leverages its proprietary protein engineering platforms to develop multifunctional biotherapeutics and antibody-drug conjugates (ADCs) for oncology. The company employs a royalty-driven portfolio model, combining internal R&D with strategic collaborations to maximize long-term value. Its lead asset, zanidatamab, is a bispecific antibody targeting HER2, currently in Phase 3 for biliary tract cancer and Phase 2 for breast cancer. Zymeworks also has early-stage ADCs, ZW191 (targeting solid tumors) and ZW251 (hepatocellular carcinoma), advancing through Phase 1. With a strong pipeline and partnerships with Jazz Pharmaceuticals and others, Zymeworks is positioned to deliver near-term catalysts.

Upcoming Catalysts (preview)

• Q4 2026Zanidatamab Phase 3 Biliary Tract Cancer Data Readout70% success
• 2027ZW191 Phase 1/2 Initial Efficacy Data50% success
• TBDPotential Partnership or Milestone Payment from Royalty Portfolio40% success